{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:51:54Z","timestamp":1762339914969},"reference-count":41,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2004,12,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To assess whether an epirubicin (EPI) -based chemotherapy plus hormonal regimen improves disease-free (DFS) in women older than 65 years, with node-positive, operable breast cancer (BC), relative to tamoxifen (TAM) alone. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> A total of 338 patients were randomly assigned after surgery to receive TAM 30 mg\/d for 3 years (TAM, n = 164), or EPI 30 mg on days 1, 8, and 15 every 28 days for six cycles plus TAM 30 mg\/d for 3 years (EPI-TAM, n = 174). In both arms, patients received radiotherapy, delivered after chemotherapy (CT) in the EPI-TAM group. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> The 6-year DFS rates were 69.3% with TAM and 72.6% with EPI-TAM (P = .14). The multivariate analysis shows a relative risk of relapse of 1.93 (95% CI, 1.70 to 2.17) with TAM compared with EPI-TAM (P = .005). The 6-year OS, related to disease progression, was 79.1% and 79.8%, respectively (P = .41). Compliance with CT was good: 96.9% of patients received six cycles. The acute toxicity per patient was mild: grade 2 neutropenia in 5.9%, grade 2 anemia in 2.0%, grade 3 nausea or vomiting in 4.6%, and grade 3 alopecia in 7.2%. Five cases (in five patients) of decreased left ventricular ejection fraction occurred after CT: three after adjuvant CT, and two after anthracycline-based CT for relapse. One patient died as a result of dysrhythmia related to carcinomatous lymphangitis. No secondary leukemia occurred. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> This study conducted in node-positive elderly patients demonstrates a significant contribution of a weekly EPI regimen in terms of DFS. Moreover, this regimen is safe for hematologic, nonhematologic, and cardiac toxicities. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2004.02.145","type":"journal-article","created":{"date-parts":[[2004,10,26]],"date-time":"2004-10-26T00:17:15Z","timestamp":1098749835000},"page":"4674-4682","source":"Crossref","is-referenced-by-count":80,"title":["Disease-Free Survival Advantage of Weekly Epirubicin Plus Tamoxifen Versus Tamoxifen Alone As Adjuvant Treatment of Operable, Node-Positive, Elderly Breast Cancer Patients: 6-Year Follow-Up Results of the French Adjuvant Study Group 08 Trial"],"prefix":"10.1200","volume":"22","author":[{"given":"Pierre","family":"Fargeot","sequence":"first","affiliation":[{"name":"From the Centre Georges-Fran\u00e7ois Leclerc, Dijon; Cetre Oscar Lambret, Lille; Institut Claudius R\u00e9gaud, Toulouse; Clinique Catherine de Sienne; Centre Ren\u00e9 Gauducheau, Nantes; Centre Jean Perrin, Clermont-Ferrand; Centre Hospitalier Andr\u00e9 Boulloche, Montb\u00e9liard; Centre Antoine Lacassagne, Nice; Centre Paul Strauss, Strasbourg; Centre Hospitalier Louis Pasteur, Colmar; Centre L\u00e9on B\u00e9rard, Lyon; and Centre Hospitalier de Bretagne Sud, Lorient, France. Dr Chapelle-Marcillac is a consultant in Chatenay..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Bonneterre","sequence":"additional","affiliation":[{"name":"From the Centre Georges-Fran\u00e7ois Leclerc, Dijon; Cetre Oscar Lambret, Lille; Institut Claudius R\u00e9gaud, Toulouse; Clinique Catherine de Sienne; Centre Ren\u00e9 Gauducheau, Nantes; Centre Jean Perrin, Clermont-Ferrand; Centre Hospitalier Andr\u00e9 Boulloche, Montb\u00e9liard; Centre Antoine Lacassagne, Nice; Centre Paul Strauss, Strasbourg; Centre Hospitalier Louis Pasteur, Colmar; Centre L\u00e9on B\u00e9rard, Lyon; and Centre Hospitalier de Bretagne Sud, Lorient, France. Dr Chapelle-Marcillac is a consultant in Chatenay..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Roch\u00e9","sequence":"additional","affiliation":[{"name":"From the Centre Georges-Fran\u00e7ois Leclerc, Dijon; Cetre Oscar Lambret, Lille; Institut Claudius R\u00e9gaud, Toulouse; Clinique Catherine de Sienne; Centre Ren\u00e9 Gauducheau, Nantes; Centre Jean Perrin, Clermont-Ferrand; Centre Hospitalier Andr\u00e9 Boulloche, Montb\u00e9liard; Centre Antoine Lacassagne, Nice; Centre Paul Strauss, Strasbourg; Centre Hospitalier Louis Pasteur, Colmar; Centre L\u00e9on B\u00e9rard, Lyon; and Centre Hospitalier de Bretagne Sud, Lorient, France. Dr Chapelle-Marcillac is a consultant in Chatenay..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Lortholary","sequence":"additional","affiliation":[{"name":"From the Centre Georges-Fran\u00e7ois Leclerc, Dijon; Cetre Oscar Lambret, Lille; Institut Claudius R\u00e9gaud, Toulouse; Clinique Catherine de Sienne; Centre Ren\u00e9 Gauducheau, Nantes; Centre Jean Perrin, Clermont-Ferrand; Centre Hospitalier Andr\u00e9 Boulloche, Montb\u00e9liard; Centre Antoine Lacassagne, Nice; Centre Paul Strauss, Strasbourg; Centre Hospitalier Louis Pasteur, Colmar; Centre L\u00e9on B\u00e9rard, Lyon; and Centre Hospitalier de Bretagne Sud, Lorient, France. Dr Chapelle-Marcillac is a consultant in Chatenay..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Campone","sequence":"additional","affiliation":[{"name":"From the Centre Georges-Fran\u00e7ois Leclerc, Dijon; Cetre Oscar Lambret, Lille; Institut Claudius R\u00e9gaud, Toulouse; Clinique Catherine de Sienne; Centre Ren\u00e9 Gauducheau, Nantes; Centre Jean Perrin, Clermont-Ferrand; Centre Hospitalier Andr\u00e9 Boulloche, Montb\u00e9liard; Centre Antoine Lacassagne, Nice; Centre Paul Strauss, Strasbourg; Centre Hospitalier Louis Pasteur, Colmar; Centre L\u00e9on B\u00e9rard, Lyon; and Centre Hospitalier de Bretagne Sud, Lorient, France. Dr Chapelle-Marcillac is a consultant in Chatenay..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Van Praagh","sequence":"additional","affiliation":[{"name":"From the Centre Georges-Fran\u00e7ois Leclerc, Dijon; Cetre Oscar Lambret, Lille; Institut Claudius R\u00e9gaud, Toulouse; Clinique Catherine de Sienne; Centre Ren\u00e9 Gauducheau, Nantes; Centre Jean Perrin, Clermont-Ferrand; Centre Hospitalier Andr\u00e9 Boulloche, Montb\u00e9liard; Centre Antoine Lacassagne, Nice; Centre Paul Strauss, Strasbourg; Centre Hospitalier Louis Pasteur, Colmar; Centre L\u00e9on B\u00e9rard, Lyon; and Centre Hospitalier de Bretagne Sud, Lorient, France. Dr Chapelle-Marcillac is a consultant in Chatenay..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Monnier","sequence":"additional","affiliation":[{"name":"From the Centre Georges-Fran\u00e7ois Leclerc, Dijon; Cetre Oscar Lambret, Lille; Institut Claudius R\u00e9gaud, Toulouse; Clinique Catherine de Sienne; Centre Ren\u00e9 Gauducheau, Nantes; Centre Jean Perrin, Clermont-Ferrand; Centre Hospitalier Andr\u00e9 Boulloche, Montb\u00e9liard; Centre Antoine Lacassagne, Nice; Centre Paul Strauss, Strasbourg; Centre Hospitalier Louis Pasteur, Colmar; Centre L\u00e9on B\u00e9rard, Lyon; and Centre Hospitalier de Bretagne Sud, Lorient, France. Dr Chapelle-Marcillac is a consultant in Chatenay..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mo\u00efse","family":"Namer","sequence":"additional","affiliation":[{"name":"From the Centre Georges-Fran\u00e7ois Leclerc, Dijon; Cetre Oscar Lambret, Lille; Institut Claudius R\u00e9gaud, Toulouse; Clinique Catherine de Sienne; Centre Ren\u00e9 Gauducheau, Nantes; Centre Jean Perrin, Clermont-Ferrand; Centre Hospitalier Andr\u00e9 Boulloche, Montb\u00e9liard; Centre Antoine Lacassagne, Nice; Centre Paul Strauss, Strasbourg; Centre Hospitalier Louis Pasteur, Colmar; Centre L\u00e9on B\u00e9rard, Lyon; and Centre Hospitalier de Bretagne Sud, Lorient, France. Dr Chapelle-Marcillac is a consultant in Chatenay..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Schraub","sequence":"additional","affiliation":[{"name":"From the Centre Georges-Fran\u00e7ois Leclerc, Dijon; Cetre Oscar Lambret, Lille; Institut Claudius R\u00e9gaud, Toulouse; Clinique Catherine de Sienne; Centre Ren\u00e9 Gauducheau, Nantes; Centre Jean Perrin, Clermont-Ferrand; Centre Hospitalier Andr\u00e9 Boulloche, Montb\u00e9liard; Centre Antoine Lacassagne, Nice; Centre Paul Strauss, Strasbourg; Centre Hospitalier Louis Pasteur, Colmar; Centre L\u00e9on B\u00e9rard, Lyon; and Centre Hospitalier de Bretagne Sud, Lorient, France. Dr Chapelle-Marcillac is a consultant in Chatenay..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Barats","sequence":"additional","affiliation":[{"name":"From the Centre Georges-Fran\u00e7ois Leclerc, Dijon; Cetre Oscar Lambret, Lille; Institut Claudius R\u00e9gaud, Toulouse; Clinique Catherine de Sienne; Centre Ren\u00e9 Gauducheau, Nantes; Centre Jean Perrin, Clermont-Ferrand; Centre Hospitalier Andr\u00e9 Boulloche, Montb\u00e9liard; Centre Antoine Lacassagne, Nice; Centre Paul Strauss, Strasbourg; Centre Hospitalier Louis Pasteur, Colmar; Centre L\u00e9on B\u00e9rard, Lyon; and Centre Hospitalier de Bretagne Sud, Lorient, France. Dr Chapelle-Marcillac is a consultant in Chatenay..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Guastalla","sequence":"additional","affiliation":[{"name":"From the Centre Georges-Fran\u00e7ois Leclerc, Dijon; Cetre Oscar Lambret, Lille; Institut Claudius R\u00e9gaud, Toulouse; Clinique Catherine de Sienne; Centre Ren\u00e9 Gauducheau, Nantes; Centre Jean Perrin, Clermont-Ferrand; Centre Hospitalier Andr\u00e9 Boulloche, Montb\u00e9liard; Centre Antoine Lacassagne, Nice; Centre Paul Strauss, Strasbourg; Centre Hospitalier Louis Pasteur, Colmar; Centre L\u00e9on B\u00e9rard, Lyon; and Centre Hospitalier de Bretagne Sud, Lorient, France. Dr Chapelle-Marcillac is a consultant in Chatenay..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Jos\u00e8phe","family":"Goudier","sequence":"additional","affiliation":[{"name":"From the Centre Georges-Fran\u00e7ois Leclerc, Dijon; Cetre Oscar Lambret, Lille; Institut Claudius R\u00e9gaud, Toulouse; Clinique Catherine de Sienne; Centre Ren\u00e9 Gauducheau, Nantes; Centre Jean Perrin, Clermont-Ferrand; Centre Hospitalier Andr\u00e9 Boulloche, Montb\u00e9liard; Centre Antoine Lacassagne, Nice; Centre Paul Strauss, Strasbourg; Centre Hospitalier Louis Pasteur, Colmar; Centre L\u00e9on B\u00e9rard, Lyon; and Centre Hospitalier de Bretagne Sud, Lorient, France. Dr Chapelle-Marcillac is a consultant in Chatenay..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Chapelle-Marcillac","sequence":"additional","affiliation":[{"name":"From the Centre Georges-Fran\u00e7ois Leclerc, Dijon; Cetre Oscar Lambret, Lille; Institut Claudius R\u00e9gaud, Toulouse; Clinique Catherine de Sienne; Centre Ren\u00e9 Gauducheau, Nantes; Centre Jean Perrin, Clermont-Ferrand; Centre Hospitalier Andr\u00e9 Boulloche, Montb\u00e9liard; Centre Antoine Lacassagne, Nice; Centre Paul Strauss, Strasbourg; Centre Hospitalier Louis Pasteur, Colmar; Centre L\u00e9on B\u00e9rard, Lyon; and Centre Hospitalier de Bretagne Sud, Lorient, France. Dr Chapelle-Marcillac is a consultant in Chatenay..."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00161-5"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(89)90849-4"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70275-6"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19941001)74:7+<2165::AID-CNCR2820741727>3.0.CO;2-6"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91075-L"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912303412706"},{"key":"R7","unstructured":"Stewart JA, Foster RS Jr: Breast cancer and aging. Semin Oncol 16:41,1989-50,"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90997-H"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03301-7"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.13.979"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1093\/geronj\/44.2.M46"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1986.tb04904.x"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1007\/BF01806004"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1104::AID-CNCR14>3.0.CO;2-1"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000801)89:3<561::AID-CNCR11>3.0.CO;2-A"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1093\/geronj\/42.2.185"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-2-200301210-00009"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2338"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.1.247"},{"key":"R20","unstructured":"Begg CB, Cohen JL, Ellerton J: Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group. Cancer Clin Trials 3:369,1980-374,"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.12.1404"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03490010059030"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.3109\/07357900009012191"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.7.1412"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.576"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.4.679"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.148"},{"key":"R28","unstructured":"Bonneterre J, Roch\u00e9 H, Kerbrat P, et al: French Adjuvant Study Group 05 trial (FEC 50  FEC 100): 10-year update of benefit\/risk ratio after adjuvant chemotherapy in node-positive, early breast cancer patients. Proc Am Soc Clin Oncol 22:24,2003,  (abstr 93)vs"},{"key":"R29","unstructured":"Snedecor GW, Cochran WG: Statistical Methods (ed 7) . Ames, IA, Iowa State University Press, 1980"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.2307\/2529425"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.9.2386"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.2307\/2344317"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Cox DR: Regression models and life-tables. J R Stat Soc B 34:187,1972-202,","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"R35","unstructured":"Albain KS, Green SJ, Ravdin PM, et al: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from Intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 21:37,2002,  (abstr 143)"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.1988"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199345050-00011"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(93)90036-Q"},{"key":"R39","unstructured":"Torti FM, Bristow MM, Lum BL, et al: Cardiotoxicity of epirubicin and doxorubicin: Assessment by endomyocardial biopsy. Cancer Res 46:3722,1986-3727,"},{"key":"R40","unstructured":"Ewer MS, Benjamin RS: Cardiac complications, in Holland J, Frei E (eds): Cancer Medicine (ed 5) . Philadelphia, PA, BC Decker, pp 2324,2000-2339"},{"key":"R41","unstructured":"Fumoleau P, Roch\u00e9 H, Kerbrat P, et al: Cardiac toxicity in operable breast cancer patients after adjuvant chemotherapy with epirubicin: 7-year analysis in 3577 patients of French Adjuvant Study Group trials. San Antonio Breast Cancer Symposium,  San Antonio, TX, December 11-14, 2002 (abstr 64)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2004.02.145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:22:49Z","timestamp":1653510169000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2004.02.145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,1]]},"references-count":41,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2004,12,1]]}},"alternative-id":["10.1200\/JCO.2004.02.145"],"URL":"https:\/\/doi.org\/10.1200\/jco.2004.02.145","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,1]]}}}